Managing kidney disease with blood-pressure control

Nature Reviews Nephrology

Volumn 7, Issue 8, 2011, Pages 434-444

  Wühl, Elke ^a   Schaefer, Franz ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CARVEDILOL; CREATININE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; LOSARTAN; METOPROLOL; NIFEDIPINE; NISOLDIPINE; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPERTENSIVE NEPHROSCLEROSIS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; META ANALYSIS; META ANALYSIS (TOPIC); MORNING DOSAGE; NEPHROSCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; RISK REDUCTION; SODIUM RESTRICTION; SURVIVAL; SYSTEMATIC REVIEW;

ADULT; ANTIHYPERTENSIVE AGENTS; CHILD; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 79961030334     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.73     Document Type: Review

References (111)

1. Klag, M. J. et al. Blood pressure and end-stage renal disease in men. N. Engl. J. Med. 334, 13-18 (1996). (Pubitemid 26012498)
2. Iseki, K., Ikemiya, Y., Iseki, C. & Takishita, S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 63, 1468-1474 (2003). (Pubitemid 36350012)
3. Locatelli, F. et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italien Cooperative Study Group. Nephrol. Dial. Transplant. 11, 461-467 (1996). (Pubitemid 26092784)
4. Remuzzi, G., Benigni, A. & Remuzzi, A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 116, 288-296 (2006). (Pubitemid 43228342)
5. Ardissino, G. et al. Epidemiology of chronic renal failure in children: Data from the ItalKid Project. Pediatrics 111, e382-e387 (2003).
6. Celedón, C. G., Bitsor, M. & Tullus, K. Progression of chronic renal failure in children with dysplastic kidneys. Pediatr. Nephrol. 22, 1014-1020 (2007). (Pubitemid 46881921)
7. Hostetter, T. H., Olson, J. L., Rennke, H. G., Venkatachalam, M. A. & Brenner, B. M. Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am. J. Physiol. 241, F85-F93 (1981). (Pubitemid 11033923)
8. Zandi-Nejad, K., Luyckx, V. A. & Brenner, B. M. Adult hypertension and kidney disease: The role of fetal programming. Hypertension 47, 502-508 (2006). (Pubitemid 43843866)
9. Takano, T. & Brady, H. R. The endothelium in glomerular inflammation. Curr. Opin. Nephrol. Hypertens. 4, 277-286 (1995).
10. Malek, A. M., Greene, A. L. & Izumo, S. Regulation of endothelin 1 gene by fluid shear stress is transcriptionally mediated and independent of protein kinase C and cAMP. Proc. Natl Acad. Sci. USA 90, 5999-6003 (1993). (Pubitemid 23191441)
11. Lee, L. K., Meyer, T. W., Pollock, A. S. & Lovett, D. H. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J. Clin. Invest. 96, 953-964 (1995).
12. Remuzzi, G. & Bertani, T. Pathophysiology of progressive nephropathies. N. Engl. J. Med. 339, 1448-1456 (1998). (Pubitemid 28516069)
13. Olbricht, C. J., Cannon, L. K., Garg, L. C. & Tisher, C. C. Activities of cathepsins B and L in isolated nephron segments from proteinuric and nonproteinuric rats. Am. J. Physiol. 250, F1055-F1062 (1986).
14. Peterson, J. C. et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann. Intern. Med. 123, 754-762 (1995).
15. Hirschberg, R. & Wang, S. Proteinuria and growth factors in the development of tubulointerstitial injury and scarring in kidney disease. Curr. Opin. Nephrol. Hypertens. 14, 43-52 (2005). (Pubitemid 40110699)
16. Wang, S. N., Lapage, J. & Hirschberg, R. Glomerular ultrafiltration and apical tubular action of IGF-1, TGF-ß, and HGF in nephrotic syndrome. Kidney Int. 56, 1247-1251 (1999). (Pubitemid 29451221)
17. Wang, S. N. & Hirschberg, R. Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis. Am. J. Physiol. Renal Physiol. 278, F554-F560 (2000). (Pubitemid 30215232)
18. Donadelli, R. et al. Protein traffic activates NF-?B gene signaling and promotes MCP-1-dependent interstitial inflammation. Am. J. Kidney Dis. 36, 1226-1241 (2000).
19. Morigi, M. et al. Protein overload-induced NF-?B activation in proximal tubular cells requires H2O2 through a PKC-dependent pathway. J. Am. Soc. Nephrol. 13, 1179-1189 (2002). (Pubitemid 34441398)
20. Zoja, C. et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am. J. Kidney Dis. 26, 934-941 (1995).
21. Kees-Folts, D., Sadow, J. L. & Schreiner, G. F. Catabolism of albumin is associated with the release of an inflammatory lipid. Kidney Int. 45, 1697-1709 (1994). (Pubitemid 24207506)
22. Zoja, C. et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-?B activation. Kidney Int. 53, 1608-1615 (1998). (Pubitemid 28243743)
23. Schalenkamp, M. A. & Danser, A. H. Angiotensin II production and distribution in the kidney: I. A kinetic model. Kidney Int. 69, 1543-1552 (2006).
24. Schalenkamp, M. A. & Danser, A. H. Angiotensin II production and distribution in the kidney-II. Model-based analysis of experimental data. Kidney Int. 69, 1553-1557 (2006).
25. Navar, L. G. & Nishiyama, A. Why are angiotensin concentrations so high in the kidney? Curr. Opin. Nephrol. Hypertens. 13, 107-115 (2004). (Pubitemid 39069906)
26. Schmitz, D. & Berk, B. C. Angiotensin II signal transduction stimulation of multiple mitogen activated protein kinase pathways. Trends Endocrinol. Metab. 8, 261-266 (1997). (Pubitemid 27424202)
27. Nitschke, R. et al. Angiotensin II increases the intracellular calcium activity in podocytes of the intact glomerulus. Kidney Int. 57, 41-49 (2000). (Pubitemid 30227752)
28. Bohrer, M. P., Deen, W. M., Robertson, C. R. & Brenner, B. M. Mechanism of the angiotensin II-induced proteinuria in the rat. Am. J. Physiol. 233, F13-F21 (1977). (Pubitemid 8171271)
29. Yoshioka, T. et al. Role of antiotensin II in overt functional proteinuria. Kidney Int. 52, 687-693 (1997).
30. Taal, M. W., Omer, S. A., Nadim, M. K. & Mackenzie, H. S. Cellular and molecular mediators in common pathway mechanisms of chronic renal disease progression. Curr. Opin. Nephrol. Hypertens. 9, 323-331 (2000). (Pubitemid 30451685)
31. Taal, M. W. et al. Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am. J. Physiol. Renal Physiol. 280, F343-F355 (2001).
32. Converse, R. L. et al. Sympathetic overactivity in patients with chronic renal failure. N. Engl. J. Med. 327, 1912-1918 (1992).
33. Hausberg, M. et al. Sympathetic nerve activity in end-stage renal disease. Circulation 165, 1974-1979 (2002). (Pubitemid 35176304)
34. Bakris, G. L. et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J. Kidney Dis. 36, 646-661 (2000).
35. Bakris, G. L. et al. Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study. Arch. Intern. Med. 15, 1555-1565 (2003). (Pubitemid 36835100)
36. Ohkubo, T. et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The Ohasama study. J. Hypertens. 20, 2183-2189 (2002). (Pubitemid 35388236)
37. Ligtenberg, G. et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N. Engl. J. Med. 340, 1321-1328 (1999). (Pubitemid 29196594)
38. Kimura, G., Dohi, Y. & Fukuda, M. Salt sensitivity and circadian rhythm of blood pressure: The keys to connect CKD with cardiovascular events. Hypertens. Res. 33, 515-520 (2010).
39. Jacob, P., Hartung, R., Bohlender, J. & Stein, G. Utility of 24-h ambulatory blood pressure measurement in a routine clinical setting of patients with chronic renal disease. J. Hum. Hypertens. 18, 745-751 (2004). (Pubitemid 39369196)
40. Timio, M. et al. 'Non-dipper' hypertensive patients and progressive renal insufficiency: A 3-year longitudinal study. Clin. Nephrol. 43, 382-387 (1995).
41. Agarwal, R., Kariyanna, S. S. & Light, R. P. Prognostic value of circadian blood pressure variation in chronic kidney disease. Am. J. Nephrol. 30, 547-553 (2009).
42. Tarver-Carr, M., Brancati, F., Eberhardt, M. & Powe, N. Proteinuria and the risk of chronic kidney disease (CKD) in the United States. J. Am. Soc. Nephrol. 11, 168A (2000).
43. Hoy, W. E., Wang, Z., vanBuynder, P., Baker, P. R. & Mathews, J. D. The natural history of renal disease in Autralian Aborigines. Part, I. Changes in albuminuria and glomerular filtration rate over time. Kidney Int. 60, 243-248 (2001). (Pubitemid 32587560)
44. Iseki, K., Kinjo, K., Iseki, C. & Takishita, S. Relationship between predicted creatinine clearance and proteinuria and the risk of devolping ESRD in Okinawa, Japan. Am. J. Kidney Dis. 44, 806-814 (2004). (Pubitemid 39445912)
45. Risdon, R. A., Sloper, J. C. & de Wardener, H. E. Relationship between renal function and histological changes found in renal biopsy specimens from patients with persistant glomerular nephritis. Lancet 2, 363-366 (1968).
46. Remuzzi, G., Ruggenenti, P. & Perico, N. Chronic renal disease: Renoprotective benefits of renin-angiotensin system inhibition. Ann. Intern. Med. 136, 604-615 (2002). (Pubitemid 34407045)
47. Ruggenenti, P. et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int. Suppl. 63, S54-S57 (1997). (Pubitemid 28020433)
48. Wingen, A. M., Fabian-Bach, C., Schaefer, F. & Mehls, O. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet 349, 1117-1123 (1997). (Pubitemid 27168544)
49. Ardissino, G. et al. Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy. Pediatr. Nephrol. 19, 172-177 (2004). (Pubitemid 38181010)
50. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349, 1857-1863 (1997).
51. Wright, J. T. Jr. et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288, 2421-2431 (2003). (Pubitemid 35340538)
52. Remuzzi, G., Ruggenenti, P. & Benigni, A. Understanding the nature of renal disease progression. Kidney Int. 51, 2-15 (1997). (Pubitemid 27064516)
53. Ruggenenti, P., Perna, A. & Remuzzi, G. Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int. 63, 2254-2261 (2003). (Pubitemid 36605839)
54. ESCAPE Trial Group; Wühl, E. et al. Strict blood pressure control and renal failure progression in children. N. Engl. J. Med. 361, 1639-1650 (2009).
55. Jafar, T. H. et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann. Intern. Med. 135, 73-87 (2001). (Pubitemid 32661190)
56. Ruggenenti, P., Schieppati, A. & Remuzzi, G. Progression, remission, regression of chronic renal diseases. Lancet 357, 1601-1608 (2001). (Pubitemid 32488830)
57. Sarnak, M. J. et al. The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the modification of diet in renal disease study. Ann. Intern. Med. 142, 342-351 (2005). (Pubitemid 40293407)
58. Chobanian, A. V. et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 289, 2560-2571 (2003).
59. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21, 1011-1053 (2003).
60. Klahr, S., Levy, A. D. & Beck, G. J. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N. Engl. J. Med. 330, 877-884 (1994). (Pubitemid 24094966)
61. Ruggenenti, P. et al. Blood pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicenter, randomized controlled trial. Lancet 365, 939-946 (2005). (Pubitemid 41071427)
62. Wright, J. T. Jr. et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288, 2421-2431 (2002). (Pubitemid 35340538)
63. Appel, L. J. et al. Intensified blood-pressure control in hypertensive chronic kidney disease. N. Engl. J. Med. 363, 918-929 (2010).
64. Schrier, R. W., Estacio, R. O., Mehler, P. S. & Hiatt, W. R. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: A summary of the ABCD trial. Nat. Clin. Pract. Nephrol. 3, 428-438 (2008).
65. Gimpel, C. et al. Superior consistency of ambulatory blood pressure monitoring in children: Implications for clinical trials. J. Hypertens. 27, 1568-1574 (2009).
66. Yusuf, S. et al. Renal outcomes with telmisartan, ramipril, or both, in patients at high vascular risk (The ONTARGET Study): A multicenter, randomized, double-blind, controlled trial. N. Engl. J. Med. 358, 1547-1559 (2008).
67. Schrier, R. W., Estacio, R. O., Esler, A. & Mehler, P. Effects of agressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 61, 1086-1097 (2002). (Pubitemid 34175478)
68. Nakao, N. et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361, 117-124 (2003). (Pubitemid 36092015)
69. Gansevoort, R. T., de Zeeuw, D. & de Jong, P. E. ACE inhibitors and proteinuria. Pharm. World Sci. 18, 204-210 (1996). (Pubitemid 27038940)
70. Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
71. Lewis, E. J., Hunsicker, L. G., Raymond, P. B. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456-1462 (1993). (Pubitemid 23335891)
72. Ross, S. D., Akhras, K. S., Zhang, S., Rozinsky, M. & Nalysnyk, L. Discontinuation of antihypertensive drugs due to adverse events: A systematic review and meta-analysis. Pharmacotherapy 21, 940-953 (2001). (Pubitemid 32747314)
73. Viberti, G., Mogensen, C. E., Groop, L. C. & Pauls, J. F. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 271, 275-279 (1994). (Pubitemid 24030753)
74. Parving, H. H., Hommel, E. & Smidt, U. M. Protection of kidney function and decrease in albuminuria by captopril in insulin-dependent diabetics with nephropathy. BMJ 297, 1086-1091 (1988).
75. Maschio, G. et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 334, 939-945 (1996). (Pubitemid 26114159)
76. Parving, H. H., Andersen, A. R., Smidt, U. M. & Svendsen, P. A. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1, 1175-1179 (1983). (Pubitemid 13092704)
77. Zucchelli, P. et al. Long-term comparison between captopril and nifidepin in the progression of renal insufficiency. Kidney Int. 42, 452-458 (1992).
78. Kamper, A. L., Strandgaard, S. & Leyssac, P. Effect of enalapril on the progression of chronic renal failure: A randomized controlled trial. Am. J. Hypertens. 5, 423-430 (1992).
79. van Essen, G. G. et al. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int. Suppl. 63, S58-S62 (1997). (Pubitemid 28020434)
80. Hannedouche, T. et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 309, 833-837 (1994). (Pubitemid 24305005)
81. Bannister, K. M., Weaver, A., Clarkson, A. R. & Woodroffe, A. J. Effect of angiotensin converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib. Nephrol. 111, 184-192 (1995).
82. Ihle, B. U. et al. Angiotensin-converting-enzyme inhibition in non-diabetic progresive renal insufficiency: A controlled double-blind trial. Am. J. Kidney Dis. 27, 489-495 (1996). (Pubitemid 26106596)
83. Ruggenenti, P. et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354, 359-364 (1999). (Pubitemid 29355751)
84. Casas, J. P. et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 366, 2026-2033 (2005). (Pubitemid 41773378)
85. Mooser, V. et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J. Cardiovasc. Pharmacol. 15, 276-282 (1990). (Pubitemid 20040586)
86. van den Meiracker, A. H. et al. Partial escape of agiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and does it affect the antihypertensive response? J. Hypertens. 10, 803-812 (1992).
87. Shiigai, T. & Shichiri, M. Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease. Am. J. Kidney Dis. 37, 477-483 (2001). (Pubitemid 32195285)
88. Bomback, A. S. & Klemmer, P. J. The incidence and implications of aldosterone breakthrough. Nat. Clin. Pract. Nephrol. 3, 486-492 (2007). (Pubitemid 47313030)
89. Burgess, E. et al. Supramaximal dose of candesartan in proteinuric kidney disease. J. Am. Soc. Nephrol. 20, 893-900 (2009).
90. Bakris, G. L. & Weir, M. R. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch. Int. Med. 160, 685-693 (2000). (Pubitemid 30140419)
91. Navaneethan, S. D., Nigwekar, S. U., Sehgal, A. R. & Strippoli, G. F. M. Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 4, 542-551 (2009).
92. Oparil, S. et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomized, double-blind trial. Lancet 370, 221-229 (2007). (Pubitemid 47069535)
93. Parving, H. H. et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446 (2008).
94. Wilmer, W. A. et al. Management of glomerular proteinuria: A commentary. J. Am. Soc. Nephrol. 14, 3217-3232 (2003). (Pubitemid 37509297)
95. Marchi, F. & Ciriello, G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: A multicenter, randomized, open-label, controlled study versus atenolol. Adv. Ther. 12, 212-221 (1995).
96. Fassbinder, W., Quarder, O. & Waltz, A. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: A multicenter randomized study. Int. J. Clin. Pract. 53, 519-522 (1999). (Pubitemid 29515823)
97. Dhaun, N. et al. Blood pressure independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 54, 113-119 (2009).
98. Bakris, G. L. et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomized controlled trial. Lancet 375, 1173-1181 (2010).
99. Doulton, T. W., He, F. J. & MacGregor, F. A. Systemic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45, 880-886 (2005). (Pubitemid 40628932)
100. Campbell, R. et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. 63, 1094-1103 (2003). (Pubitemid 36315589)
101. MacKinnon, M. et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am. J. Kidney Dis. 48, 8-20 (2006).
102. Hermida, R. C., Calvo, C., Ayala, D. E. & Lopez, J. E. Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension 46, 960-968 (2005).
103. Muntner, P., Coresh, J., Clinton Smith, J., Eckfeldt, J. & Klag, M. J. Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities Study. Kidney Int. 58, 293-301 (2000). (Pubitemid 30429874)
104. de Brito-Ashurst, I., Varagunam, M., Raftery, M. J. & Yaqoob, M. M. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J. Am. Soc. Nephrol. 20, 2075-2084 (2009).
105. Ritz, E., Gross, M. L. & Dikow, R. Role of calcium-phosphorous disorders in the progression of renal failure. Kidney Int. 68 (Suppl. 99), S66-S70 (2005).
106. Fliser, D., Bahlmann, F. H. & Haller, H. EPO: Renoprotection beyond anemia correction. Pediatr. Nephrol. 21, 1785-1789 (2006). (Pubitemid 44741154)
107. Wright, J. T. J. et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA 288, 2421-2431 (2002).
108. Maschio, G. et al. Effect of angiotensin-converting-enzme inhibitor benazepril on the progression of chronic renal insufficiency. N. Engl. J. Med. 334, 939-945 (1996). (Pubitemid 26114159)
109. Hou, F. F. et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 354, 131-140 (2006).
110. Mann, J. F. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372, 547-553 (2008).
111. Jafar, T. H. et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-meta-analysis. Ann. Intern. Med. 139, 244-252 (2003).